Oral Presentation Asia Pacific Stroke Conference 2024

Precise Antiplatelet Therapy Guided by Platelet Aggregation Function in Ischemic Stroke (107579)

Yapeng Lin 1 2 , Song He 1 , Quandan Tan 1 , Fengkai Mao 1 , hongwei deng 1 , xiaoling chen 3 , Craig Anderson 4 5 , Jie Yang 3 6
  1. The First Affiliated Hospital of Chengdu Medical College, Chengdu, CHINA, China
  2. International Clinical Research Center, Chengdu Medical College, Chengdu, China
  3. Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
  4. The George Institute for Global Health, Stroke, Beijing
  5. The University of New South Wales, Sydney
  6. Sichuan Provincial Key Laboratory for Human Disease Gene Study, Chengdu, China

Background and aims:

The antiplatelet drug resistance is not conducive to the secondary prevention of non-cardiac ischemic stroke. Therefore, PATH STROKE trial was conducted to explore the effectiveness and safety of precise antiplatelet therapy guided by platelet aggregation function in patients with non-cardiac ischemic stroke.

Methods:

An ongoing multi-centre, prospective, randomised, open-label, blinded endpoint trial of precise antiplatelet therapy in patients with non-cardiac stroke in regions of China. About 50 hospitals from China were selected to enroll patients, with a total of 3524 patients.Patients are randomised through a mobile phone digital system to precise antiplatelet (guided by platelet aggregation function) or guideline-recommended antiplatelet management. Primary outcome measure is major ischemic events and major bleeding events, including cardiovascular and cerebrovascular death, myocardial infarction, stroke, emergency intervention, stent thrombosis, and Bleeding Academic Research Consortium (BARC) grade 2 or higher hemorrhage. The patients were followed up for 6 months and 12 months.

Results:

From June 2023 to june 2024, 743 patients were recruited, including 368 in the standard group and 375 in the precision group. The independent DSMB has recommended continuation of the trial as no safety concerns have been identified to date. We expect to complete this study by the end of 2025.

Conclusions:

PATH STROKE will provide new and high-quality evidence-based medical evidence for precise antiplatelet therapy under the guidance of platelet aggregation function in ischemic stroke. Trial registration: ClinicalTrials.gov NCT06269432; Chinese Trial Registry ChiCTR2200066530.